Using real world data to assess cardiovascular outcomes of two antidiabetic treatment classes

Table 1 Patient characteristics and results before correcting for potential confounding factors

	SGLT2	Control
n	46909	189120
Mean age	59	66
SD age	11	13
Percent male	53%	52%
Comorbidities
Hypertension (I10)	45%	41%
CKD (N18)	4%	8%
Co-medication
On insulin	32%	19%
On metformin	52%	33%
LDL cholesterol (mg/dL)	91.6	93.1
HDL cholesterol (mg/dL)	43.6	43.2
After index event
Total stroke (I63) or MI (I21)	12347 (5.2%)
n in group	1667	10680
Percent in group	3.60%	5.60%
RR SGLT2 vs control	0.63

SGLT2: Sodium-glucose co-transporter-2; RR: Risk ratio; SD: Standard deviation; CKD: Chronic kidney disease; LDL: Low density lipoprotein; HDL: High density lipoprotein; MI: Myocardial infarction.